Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of RUC-4 Succinate, a Novel αIIbβ3 Pure Antagonist for First Point of Contact Treatment of ST Segment Elevated Myocardial Infarction (STEMI)
Document Type
Abstract
Publication Date
11-29-2018
Recommended Citation
Vootukuri, S., Li, J., Nedelman, M., Babayeva, M., & Coller, B. S. (2018). Pharmacokinetic (PK) and pharmacodynamic (PD) studies of RUC-4 succinate, a novel αIIbβ3 pure antagonist for first point of contact treatment of ST segment elevated myocardial infarction (STEMI) [Abstract]. Blood, 132(Supplement 1) 1243. Retrieved from http://www.bloodjournal.org/content/132/Suppl_1/1243
COinS
